Wedbush Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its price target lifted by Wedbush from $187.00 to $191.00 in a note issued to investors on Wednesday,MarketScreener reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Wedbush’s price objective would suggest a potential upside of 4.04% from the stock’s previous close.

Several other research firms have also recently commented on BIIB. Barclays initiated coverage on shares of Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 target price for the company. Truist Financial increased their price target on shares of Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a research note on Monday, February 9th. The Goldman Sachs Group restated a “buy” rating on shares of Biogen in a report on Monday, February 9th. Mizuho upped their target price on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Biogen in a research note on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $207.96.

Biogen Trading Up 0.1%

NASDAQ BIIB opened at $183.58 on Wednesday. The company has a market capitalization of $26.94 billion, a price-to-earnings ratio of 20.67, a PEG ratio of 1.49 and a beta of 0.15. The stock’s 50-day simple moving average is $186.19 and its two-hundred day simple moving average is $170.98. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the firm earned $3.44 EPS. The company’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts forecast that Biogen will post 15.83 EPS for the current fiscal year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Several institutional investors and hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new position in shares of Biogen in the 4th quarter worth about $464,408,000. Boston Partners purchased a new stake in Biogen during the 4th quarter valued at about $302,815,000. Fred Alger Management LLC increased its stake in Biogen by 39,074.8% during the 4th quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after purchasing an additional 796,735 shares in the last quarter. Employees Provident Fund Board bought a new stake in Biogen during the 4th quarter valued at about $123,931,000. Finally, Orion Porfolio Solutions LLC raised its holdings in Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after buying an additional 509,809 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Canaccord raised its price target on BIIB to $245 and reiterated a Buy rating, implying meaningful upside versus current levels — a bullish analyst signal that can support share gains. Canaccord raises BIIB PT to $245Article
• Positive Sentiment: FDA approved a higher‑dose SPINRAZA regimen, strengthening Biogen’s rare‑disease franchise and supporting longer‑term revenue potential from SMA treatments. FDA clears higher‑dose SPINRAZAArticle
• Neutral Sentiment: Biogen agreed to acquire Apellis for ~$5.6B in cash (plus potential contingent payments), adding commercial immunology and nephrology assets (SYFOVRE, EMPAVELI) that bolster growth strategy but require execution and integration. Biogen to buy Apellis for $5.6BArticle
• Neutral Sentiment: Market reaction: Apellis stock surged (big premium to APLS holders), validating the bid price, but the takeover effectively caps Apellis upside — an outcome analysts note while weighing Biogen’s strategic gain versus cash outlay. Apellis hits 2‑year high after Biogen dealArticle
• Negative Sentiment: A law firm launched an investor probe into the proposed Apellis sale, creating potential legal/transactional friction and additional uncertainty around deal process or pricing. Investor alert — probe into Apellis saleArticle
• Negative Sentiment: Several analysts remain cautious on Biogen (and some on Apellis), keeping Hold/neutral ratings and warning the deal may cap upside or not materially change near‑term catalysts — this analyst skepticism can weigh on BIIB near term. Analysts remain cautious despite positivesArticle

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.